PROJECT SUMMARY Over the past four years, our U19 AG060917 has evolved from being multi–disciplinary to a transdisciplinary program that has begun to enable team science encompassing aging epidemiology, bone biology, adipose tissue biology and the neurosciences. Based at three primary sites in the U.S.––Icahn School of Medicine at Mount Sinai, Maine Medical Center Research Institute, and University of California at San Francisco––the U19 receives collaborative input from Harvard Medical School, U.S. Department of Agriculture, University of Leiden, Icelandic Heart Association, Columbia University, and, importantly, the National Institute on Aging. The overall thrust that now integrates disciplines ranging from physical chemistry, biochemistry and pharmacology, to complex mouse genetics, to case–cohort studies in people necessitates a mechanism that will not only maintain connectivity between the groups over time, but also, more importantly, enable true synergy. Thus, one function of the Administrative, Biostatistical and GLP Management Core (Core C) is to provide overarching leadership, coordination and support across all sites. This has already been achieved under the joint leadership of Drs. Zaidi and Rosen and will continue in earnest. For further seamlessness, Core C has put in place a purposefully–crafted administrative structure for budget management, personnel management, general scheduling and communication, and record maintenance. Dedicated biostatistical support will ensure conformity of statistical procedures across multiple sites, and together with the MediaLab Document Control System (Core A), will facilitate data re–analysis and cross–institutional validation. For Projects that require analysis or re–analysis of RNA sequencing data, Core C will provide bioinformatics support. Finally, we have recently expanded Core C to include the management of our new Good Laboratory Practice (GLP) Platform. This platform has a separate GLP lab, is supported by an independent Quality Assurance Program, and complies with the Code of Federal Regulations, Title 21, Part 58. The platform will allow the proposed studies to be carried out under the strictest standards––which we consider not only a step forward towards full transparency and rigor but is also key to the movement of our therapeutic FSH–blocking antibody, MS-Hu6, into the clinic. In all, Core C, which is now matrixed within the Center for Translational Medicine and Pharmacology of which Dr. Zaidi is Director, has become a vital overarching component of all U19 Projects and both Cores.